SCHEMBL2307007

SCHEMBL2307007

NC(=O)N[C@H](CO)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 3/20 0.68
CA2 P00918 4/20 0.44
CA1 P00915 3/20 0.44
MME P08473 6/20 0.44
CAD P27708 1/20 0.37
FOLH1 Q04609 1/20 0.37
RIMKLA Q8IXN7 1/20 0.37
NAALAD2 Q9Y3Q0 1/20 0.37
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
ALOX15 P16050 1/20 0.37
NFKB1 P19838 1/20 0.37
PTGS2 P35354 1/20 0.37
THPO P40225 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
OR51E2 Q9H255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2793959 1.00 TGFBR1 (0.68) TGFBR1CA2CA1MMECAD
SCHEMBL2793957 1.00 TGFBR1 (0.68) TGFBR1CA2CA1MMECAD
SCHEMBL9952519 0.82 TGFBR1 (0.46) TGFBR1CA2CA1CADNFKB1
SCHEMBL1147073 0.81 TGFBR1 (0.47) TGFBR1CADFOLH1RIMKLANAALAD2
SCHEMBL1147075 0.81 TGFBR1 (0.47) TGFBR1CADFOLH1RIMKLANAALAD2
SCHEMBL27637802 0.79 TGFBR1 (0.60) TGFBR1CA2CA1MMEFOLH1
SCHEMBL21950137 0.79 TGFBR1 (0.60) TGFBR1CA2CA1MMEFOLH1
SCHEMBL14050302 0.79 TGFBR1 (0.60) TGFBR1CA2CA1MMEFOLH1
SCHEMBL17987676 0.78 TGFBR1 (0.43) TGFBR1CA2CA1MMECAD
SCHEMBL5493514 0.78 CA2 (0.52) TGFBR1CA2CA1MMEFOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1376202-A Stereostructure of decarbamylase and use thereof KANEGAFUCHI CHEMICAL IND (JP) 2002-10-23 CN claimed
EP-1209234-A1 STEREOSTRUCTURE OF DECARBAMYLASE AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2002-05-29 EP claimed
CN-119842679-A D-threonine aldolase mutant and application thereof 绵阳晟氏健康科技有限公司 2025-04-18 CN disclosed
CN-116287044-A Application of D-threonine aldolase in preparation of D-serine 弈柯莱生物科技(上海)股份有限公司 2023-06-23 CN disclosed
EP-1331274-B1 PROCESS FOR PRODUCING D-SERINE KYOWA HAKKO BIO CO LTD (JP) 2011-08-03 EP disclosed
US-20110065794-A1 Wrinkle-preventing and improving composition SHISEIDO COMPANY, LTD. (JP) 2011-03-17 US disclosed
US-20100168468-A1 WRINKLE-PREVENTING AND IMPROVING COMPOSITION KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-07-01 US disclosed
CN-101227885-A Wrinkle preventing/improving agent SHISEIDO CO LTD (JP) 2008-07-23 CN disclosed
EP-1908454-A1 WRINKLE-PREVENTIVE/AMELIORATING AGENT SHISEIDO COMPANY, LTD. (JP) 2008-04-09 EP disclosed
EP-1616945-B1 Process for producing D-N-carbamoyl-alpha-amino acids KANEGAFUCHI CHEMICAL IND (JP) 2007-11-21 EP disclosed
US-7186532-B2 Process for producing D-serine KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-03-06 US disclosed
EP-0801131-B1 PROCESS FOR PRODUCING D-N-CARBAMOYL-ALPHA-AMINO ACID KANEGAFUCHI CHEMICAL IND (JP) 2007-02-21 EP disclosed
EP-1616945-A1 Process for producing D-N-carbamoyl-alpha-amino acids KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2006-01-18 EP disclosed
EP-1616946-A1 Process for producing D-N-carbamoyl-alpha-amino acids KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2006-01-18 EP disclosed
US-20040072308-A1 Process for producing d-serine KYOWA HAKKO BIO CO., LTD. (JP) 2004-04-15 US disclosed
EP-1331274-A1 PROCESS FOR PRODUCING D-SERINE KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-07-30 EP disclosed
CN-1376202-A Stereostructure of decarbamylase and use thereof KANEGAFUCHI CHEMICAL IND (JP) 2002-10-23 CN disclosed
EP-1209234-A1 STEREOSTRUCTURE OF DECARBAMYLASE AND METHOD OF USING THE SAME Kaneka Corporation (JP) 2002-05-29 EP disclosed
EP-0801131-A1 PROCESS FOR PRODUCING D-N-CARBAMOYL-$g(a)-AMINO ACID Kanegafuchi Chemical Industry Co., Ltd. (JP) 1997-10-15 EP disclosed
US-4237227-A ENZYMATIC HYDROLYSIS OF A HYDANTOIN KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1980-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168468-A1 WRINKLE-PREVENTING AND IMPROVING COMPOSITION COL1A1, COL2A1, COL14A1 TGFBR1 412/4885CA2 2434/4885CA1 4069/4885
US-20110065794-A1 Wrinkle-preventing and improving composition COL1A1, COL2A1, COL14A1 TGFBR1 412/4885CA2 2434/4885CA1 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.